文献速递甲状腺疾病

限制性诊断策略人群中原位主动监测用于甲状腺微小乳头状癌的适用性

Active Surveillance for Papillary Thyroid Microcarcinoma in a Population with Restrictive Diagnostic Workup Strategies.
PubMed 文献 · Thyroid · 2021-02-23

该研究基于荷兰癌症登记数据库2005–2015年1018例手术确诊的甲状腺微小乳头状癌(mPTC)患者,按术前转移、偶然发现及术前高度可疑或确诊mPTC分为三组,仅第三组199例被视为主动监测(AS)潜在候选者,其中13.6%有淋巴结转移,初始治疗后复发率3.5%。结论认为在限制性诊断流程国家AS适用患者有限且淋巴结转移率较高,但个体化仍可考虑AS。

要点

  • 限制性诊断流程下仅199/1018例mPTC为AS潜在候选者。
  • 第三组候选者中13.6%存在淋巴结转移,初始治疗后3.5%复发。
  • 在荷兰等限制性诊断国家AS附加价值有限,可个体化提供。

核心结论

  • 限制性小甲状腺结节诊断策略导致符合AS条件的患者有限且淋巴结转移发生率更高。
  • 在荷兰等限制性诊断指南国家,AS的附加价值有限。
  • 若发现mPTC,可在个体化基础上提供AS。

研究设计与样本

  • 基于荷兰癌症登记数据库的回顾性队列研究,纳入2005–2015年所有手术确诊的mPTC患者共1018例。
  • 按术前转移(Group 1)、其他指征手术后病理发现(Group 2)、术前高度可疑或确诊mPTC(Bethesda 5或6,Group 3)分三组。
  • 仅Group 3的199例被视为AS潜在候选者。

主要发现

  • Group 1共152例术前发现转移。
  • Group 2共667例,其中16例(2.4%)有淋巴结转移。
  • Group 3共199例,其中27例(13.6%)有淋巴结转移。
  • Group 3初始治疗后3.5%(7/199)患者复发。

关键数值与推荐

  • AS潜在候选者定义为术前高度可疑甲状腺结节或确诊mPTC(Bethesda 5或6)。
  • Group 2淋巴结转移比例2.4%(16/667)。
  • Group 3淋巴结转移比例13.6%(27/199),复发比例3.5%(7/199)。

临床怎么用

  • 在限制性诊断流程人群中,筛选AS候选者需严格评估术前淋巴结状态。
  • 对符合Group 3定义的mPTC患者,可与患者个体化讨论AS的获益与风险。
  • 限制性诊断策略下不应广泛推广AS,需结合本地诊断流程评估。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The worldwide incidence of papillary thyroid carcinoma (PTC) has increased. Efforts to reduce overtreatment follow two approaches: limiting diagnostic workup of low-risk thyroid nodules and pursuing active surveillance (AS) after diagnosis of microscopic PTC (mPTC). However, most studies on AS have been performed in countries with a relatively high proportion of overdiagnosis and thus incidental mPTC. The role of AS in a population with a restrictive diagnostic workup protocol for imaging and fine-needle aspiration remains unknown. Therefore, the aim of this study was to describe the proportion and characteristics of patients with mPTC in the Netherlands and to describe the potential candidates for AS in a situation with restrictive diagnostic protocols since 2007. Methods: All operated patients with an mPTC in the Netherlands between 2005 and 2015 were identified from the Netherlands Cancer Registry database. Three groups were defined: (Group 1) mPTC with preoperative distant or lymph node metastases, (Group 2) mPTC in pathology report after thyroid surgery for another indication, and (Group 3) patients with a preoperative high suspicious thyroid nodule or proven mPTC (Bethesda 5 or 6). Only patients in Group 3 were considered potential candidates for AS. Results: A total of 1018 mPTC patients were identified. Group 1 consisted of 152 patients with preoperatively discovered metastases. Group 2 consisted of 667 patients, of whom 16 (2.4%) had lymph node metastases. There were 199 patients in Group 3, of whom 27 (13.6%) had lymph node metastases. After initial treatment in Group 3, 3.5% (7/199) of the patients had recurrence. Conclusions: Restrictive diagnostic workup strategies of patients with small thyroid nodules lead to limited patients eligible for AS and a higher incidence of lymph node metastases. We believe that there is limited additive value for AS in countries with restrictive diagnostic workup guidelines such as in the Netherlands. However, if an mPTC is encountered, AS can be offered on an individual basis.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lončar I, van Dijk SPJ, Metman MJH, et al. Active Surveillance for Papillary Thyroid Microcarcinoma in a Population with Restrictive Diagnostic Workup Strategies. Thyroid. 2021. PMID: 33430696. doi:10.1089/thy.2020.0845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。